Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NHLBI TOPMed: Determining the association of chromosomal variants with non-PV triggers and ablation-outcome in AF-DECAF

ABSTRACT: NHLBI TOPMed: Determining the association of chromosomal variants with non-PV triggers and ablation-outcome in AF-DECAF

PROVIDER: PRJNA434163 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

NHLBI TOPMed: Determining the association of chromosomal variants with non-PV triggers and ablation-outcome in AF-DECAF

Project description:NHLBI TOPMed: Determining the association of chromosomal variants with non-PV triggers and ablation-outcome in AF-DECAF

| PRJNA434164 | ENA

NHLBI TOPMed: The Vanderbilt AF Ablation Registry

Project description:<p>The Vanderbilt Atrial Fibrillation Ablation Registry (VAFAR) was founded in 2011. Patients with AF referred for AF ablation are prospectively enrolled. A detailed clinical history is recorded, along with imaging data (cardiac MRI or CT). Blood samples are obtained for DNA extraction at the time of ablation. Details of the ablation procedure are recorded. Patients are longitudinally followed to monitor for AF recurrence. VAFAR contributed 171 samples submitted to dbGaP for WGS: 115 were from male subjects, of which 113 were white/non-Hispanic and 2 were Hispanic; 56 were from females, of which all 56 were white/non-Hispanic.</p>

| phs000997 | dbGaP

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt Atrial Fibrillation Ablation Registry

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt Atrial Fibrillation Ablation Registry

| PRJNA297607 | ENA

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study

| PRJNA309734 | ENA

Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation

Project description:Background: Genomic and experimental studies suggest a role for PITX2 in atrial fibrillation (AF). To assess whether this association is relevant for recurrent AF in patients, we tested whether left atrial PITX2 affects recurrent AF after AF ablation. Methods: mRNA concentrations of PITX2 and its cardiac isoform, PITX2c, were quantified in left atrial appendages (LAA) from patients undergoing thoracoscopic AF ablation, either in whole LAA tissue (n=83) or in LAA cardiomyocytes (n=52), and combined with clinical parameters to predict AF recurrence. Literature suggests bone morphogenetic protein 10 (BMP10) as a PITX2-repressed, atrial-specific, secreted protein. BMP10 plasma concentrations were combined with eleven cardiovascular biomarkers and clinical parameters to predict recurrent AF after catheter ablation in 359 patients. Results: Reduced cardiomyocyte PITX2 concentrations, but not whole LAA tissue PITX2, were associated with AF recurrence after thoracoscopic AF ablation (16% decreased recurrence per 2-(ΔΔCt) increase in PITX2). RNA sequencing, qPCR and Western blotting confirmed BMP10 as one of most PITX2-repressed atrial genes. Left atrial size (hazard ratio per mm increase, HR [95%CI] 1.055 [1.028, 1.082], non-paroxysmal AF (HR 1.672 [1.206, 2.318]) and elevated BMP10 (HR 1.339 [CI 1.159, 1.546] per quartile increase) were predictive of recurrent AF. BMP10 outperformed eleven other cardiovascular biomarkers in predicting recurrent AF. Conclusions: Reduced left atrial cardiomyocyte PITX2 and elevated plasma concentrations of the PITX2-repressed, secreted, atrial protein BMP10 identify patients at risk of recurrent AF after ablation.

2020-06-19 | GSE152181 | GEO

Identification of ERα AF-1 or AF-2 mediated genes in mouse uterus

Project description:Estrogen receptor alpha (ERα) is a ligand dependent transcription regulator, which contains two transactivation functional domains, AF-1 and AF-2. These activities are regulated differently by the ligands. Specifically, the selective estrogen receptor modulators (SERMs) regulate AF-1 rather than AF-2. It is important to know whether AF-1/AF-2 predominantly regulated genes exist in the tissues for a better understanding of the SERMs functionality. We sought out AF-1 dependent estrogenic genes by using the AF-2 mutated knock-in (KI) mouse model, AF2ERKI. AF2ER is an estrogen-insensitive AF-2 disrupted ERα mutant mouse but unique to this model, AF-1 can be activated by the estrogen-antagonist, fulvestrant (ICI), in vitro and in vivo. The information of ICI-mediated gene expression profile of AF2ERKI could define whether AF-1/AF-2 predominantly regulated genes exist in the tissues.

2020-12-01 | GSE138443 | GEO

NHLBI TOPMed: Outcome Modifying Gene in SCD (OMG-SCD)

Project description:NHLBI TOPMed: Outcome Modifying Gene in SCD (OMG-SCD)

| PRJNA472123 | ENA

NHLBI TOPMed: Outcome Modifying Gene in SCD (OMG-SCD)

Project description:NHLBI TOPMed: Outcome Modifying Gene in SCD (OMG-SCD)

| PRJNA472122 | ENA

Microsecond pulsed electric fields induce myocardial ablation by damaging mitochondria

Project description:Catheter ablation is an effective treatment to prevent recurrence of Atrial fibrillation (AF) and can be used to maintain sinus rhythm and improve symptoms of AF, but to some extent it can cause a range of adverse effects associated with catheter ablation. Pulsed electric field is a newer treatment modality to replace catheter ablation for atrial fibrillation due to its fewer side effects. Different from radiofrequency ablation, which destroys diseased myocardial tissue by thermal energy, pulsed electric field ablation achieves the purpose of atrial fibrillation ablation by inducing damage to diseased myocardial cells through irreversible electroporation. However, some experimental parameters and mechanism of pulsed electric fields remain unclear.

2023-11-30 | GSE214387 | GEO

NHLBI TOPMed: Partners HealthCare Biobank

Project description:NHLBI TOPMed: Partners HealthCare Biobank

| PRJNA300701 | ENA